BPMC Blueprint Medicines Corp

Price (delayed)

$52.21

Market cap

$3.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.08

Enterprise value

$3.18B

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company ...

Highlights
BPMC's gross profit has dropped by 77% year-on-year but it is up by 21% since the previous quarter
Blueprint Medicines's revenue has shrunk by 73% YoY but it has increased by 23% QoQ
Blueprint Medicines's equity has decreased by 37% YoY and by 9% QoQ
BPMC's debt is up by 25% year-on-year

Key stats

What are the main financial stats of BPMC
Market
Shares outstanding
59.57M
Market cap
$3.11B
Enterprise value
$3.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.51
Price to sales (P/S)
14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.36
Earnings
Revenue
$221.24M
EBIT
-$649.28M
EBITDA
-$635.96M
Free cash flow
-$309.67M
Per share
EPS
-$11.08
Free cash flow per share
-$5.22
Book value per share
$14.89
Revenue per share
$3.73
TBVPS
$19.28
Balance sheet
Total assets
$1.14B
Total liabilities
$261.64M
Debt
$109.52M
Equity
$881.67M
Working capital
$550.22M
Liquidity
Debt to equity
0.12
Current ratio
5.02
Quick ratio
4.56
Net debt/EBITDA
-0.11
Margins
EBITDA margin
-287.5%
Gross margin
84.6%
Net margin
-294%
Operating margin
-292.7%
Efficiency
Return on assets
-47.8%
Return on equity
-58.7%
Return on invested capital
-65.8%
Return on capital employed
-64.5%
Return on sales
-293.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPMC stock price

How has the Blueprint Medicines stock price performed over time
Intraday
-2.34%
1 week
-1.55%
1 month
-7.25%
1 year
-40.39%
YTD
-51.26%
QTD
-18.27%

Financial performance

How have Blueprint Medicines's revenue and profit performed over time
Revenue
$221.24M
Gross profit
$187.26M
Operating income
-$647.55M
Net income
-$650.37M
Gross margin
84.6%
Net margin
-294%
BPMC's gross profit has dropped by 77% year-on-year but it is up by 21% since the previous quarter
Blueprint Medicines's revenue has shrunk by 73% YoY but it has increased by 23% QoQ
BPMC's net margin is up by 18% since the previous quarter
The operating margin has increased by 18% from the previous quarter

Growth

What is Blueprint Medicines's growth rate over time

Valuation

What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
3.51
P/S
14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.36
The price to book (P/B) is 40% lower than the 5-year quarterly average of 6.0 and 27% lower than the last 4 quarters average of 4.9
Blueprint Medicines's equity has decreased by 37% YoY and by 9% QoQ
The P/S is 85% below the 5-year quarterly average of 95.4 and 50% below the last 4 quarters average of 28.6
Blueprint Medicines's revenue has shrunk by 73% YoY but it has increased by 23% QoQ

Efficiency

How efficient is Blueprint Medicines business performance
Blueprint Medicines's return on sales has increased by 18% QoQ
BPMC's return on equity is down by 13% since the previous quarter
The company's return on assets fell by 10% QoQ
The ROIC has increased by 3.7% from the previous quarter

Dividends

What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPMC.

Financial health

How did Blueprint Medicines financials performed over time
BPMC's quick ratio is down by 43% year-on-year but it is up by 31% since the previous quarter
Blueprint Medicines's current ratio has decreased by 40% YoY but it has increased by 36% from the previous quarter
BPMC's debt is 88% smaller than its equity
BPMC's debt to equity has surged by 100% year-on-year and by 9% since the previous quarter
Blueprint Medicines's equity has decreased by 37% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.